Incyte (INCY) Long-Term Debt Repayments (2010 - 2013)

Incyte's (INCY) quarterly Long-Term Debt Repayments came in at $488.7 million in Q4 2013, up 4225.06% on a QoQ basis from $11.3 million in Q3 2013.

Analysis

Incyte (INCY) Long-Term Debt Repayments (2010 - 2013) Analysis & Trends

Incyte (INCY) has 2 years of Long-Term Debt Repayments data on file, last reported at $488.7 million in Q4 2013.

Quarterly Long-Term Debt Repayments changed N/A year-over-year to $488.7 million in Q4 2013, while the trailing twelve-month figure through Dec 2013 was $509.8 million (changed N/A YoY) and the FY2014 annual result came in at $300000.0, down 99.94% from the prior year.
Long-Term Debt Repayments grew to $488.7 million in Q4 2013, from $11.3 million in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $488.7 million in Q4 2013 to a low of $9.8 million in Q2 2013.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	-
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	17.05 Mn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-
10	Incyte	25.44 Bn	20.91 Bn	1.57 Bn	-

Historic Data

Download Data